Top Adcock shareholders back CFR deal; Cubist wins FDA nod for new Entereg use; Chinese pharmas report profits slump;

@FiercePharma: Two most popular profiles from our Top 10 generics makers report: Teva and Sandoz | Follow @FiercePharma

@CarlyHFierce: Check out the top 10 DTC pharma advertisers from 2013 H1 in the new report. | Follow @CarlyHFierce

> Four Adcock Ingram investors say they're backing a $1.3 billion buyout offer from the Chilean drugmaker CFR Pharmaceuticals; the South African company's biggest shareholder, however, has said it would prefer a domestic owner. Report

> Cubist Pharmaceuticals ($CBST) won FDA approval for expanded use of Entereg, a drug used to speed healing after bowel surgery. Report

> The Finnish drugmaker Orion posted a 12% drop in operating profits for the quarter, to €67 million (about $92 million), thanks to generic competition for its Parkinson's drug. Report

> China's Guangxi Wuzhou Zhongheng Group posted a 29% increase in 9-month net profits to about $92 million. Report

> China's Jiangzhong Pharmaceuticals said its 9-month net profits had dropped 6.8% to 139.2 million yuan, or about $23 million. Report

> India's Symbiotec Pharmalab got a $48 million influx from the private equity firm Actis, which purchased a "significant" stake in the company. Report

Medical Device News

@FierceMedDev: New special report: Top Med Tech Investments of Q3. Report | Follow @FierceMedDev

@MarkHFierce: For Boston Scientific, the first vaginal mesh implant lawsuits are slated to begin in March. Will the company settle? Item | Follow @MarkHFierce

@MichaelGFierce: Implantable, light-sensitive hydrogel could help treat diabetes. More from FierceDrugDelivery | Follow @MichaelGFierce

> Qiagen inks lung cancer diagnostics deal with Clovis Oncology. Story

> CareFusion's latest malfunction draws FDA's most serious label. Article

> European Parliament advances regs that would strengthen scrutiny of high-risk devices. News

> With FDA nod, Cardiovascular Systems targets $1.5B market. More

Biotech News

@FierceBiotech: ICYMI yesterday: 20 BigPharma and biotech mobile apps - 2013. Report | Follow @FierceBiotech

@JohnCFierce: Good thing we have archives--Pain surges after Pfizer commits to 3rd try for long-delayed pain drug Remoxy. Story | Follow @JohnCFierce

@DamianFierce: It's another Class I recall for CareFusion, and these things are starting to catch up with revenue, it seems. News | Follow @DamianFierce

> Novartis grabs an option to buy biotech startup for up to $300M. Story

> Gene therapy upstart launches with $50M and long-term commercial goals. More

> FDA gives J&J a thumbs-up--with a catch--on hep C drug simeprevir. Article

Biotech Research News

@EmilyMFierce:  | Follow @EmilyMFierce

> Harvard, AstraZeneca partner to replace animal testing with 'organs-on-chips.' More

> Takeda, Hopkins developing new pancreatic cancer drugs. Story

> Novartis CDK 4/6 cancer drug effective in preclinical tests, advances to PhI. Item

> New approach could lead to universal flu vaccine. Article

> Mini pancreas grown in lab using mouse cells. Story

Pharma Manufacturing News

@EricPFierce: Is there a connection between pharma DTC spending and job cuts? In some cases, yes. FiercePharma special report | Follow @EricPFierce

> U.K. takes enforcement action against third Wockhardt plant. More

> Authorities seize large load of fake Xanax headed for Egypt. Story

> Teva API plant workers strike over wage gaps. Article

> German contract manufacturers invest €70 million on expansions. Item

> Teva opens $100M Croatia plant as it cuts elsewhere. Report

> Biocad taking biosimilar production to Brazil. More

And Finally... Want big hair? Researchers have found a new way to grow it, at least in mice. Report (sub. req.)

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."